UTHR
NASDAQ · Biotechnology
United Therapeutics Corp
$531.82
+10.60 (+2.03%)
Financial Highlights (FY 2026)
Revenue
2.56B
Net Income
1.07B
Gross Margin
89.2%
Profit Margin
41.5%
Rev Growth
+19.5%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.2% | 89.2% | 63.2% | 63.2% |
| Operating Margin | 47.9% | 43.1% | 18.6% | 18.9% |
| Profit Margin | 41.5% | 39.5% | 14.9% | 13.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.56B | 2.15B | 2.73B | 2.22B |
| Gross Profit | 2.29B | 1.91B | 1.73B | 1.40B |
| Operating Income | 1.23B | 924.31M | 507.41M | 420.44M |
| Net Income | 1.07B | 802.14M | 406.29M | 307.07M |
| Gross Margin | 89.2% | 89.2% | 63.2% | 63.2% |
| Operating Margin | 47.9% | 43.1% | 18.6% | 18.9% |
| Profit Margin | 41.5% | 39.5% | 14.9% | 13.8% |
| Rev Growth | +19.5% | +19.5% | +4.0% | +2.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 457.25M | 457.25M | 6.76B | 6.24B |
| Total Equity | 9.81B | 9.81B | 12.89B | 12.35B |
| D/E Ratio | 0.05 | 0.05 | 0.52 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 1.31B | 1.04B | 733.08M | 605.29M |
| Free Cash Flow | — | — | 513.48M | 304.80M |